More People Than Ever Taking GLP-1 Drugs for Weight Loss

Growing List of Diseases Now Indicated as Treatable With GLP-1 Drugs

KELOWNA, BC / ACCESS Newswire / June 17, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following glucagon-like peptide-1 ("GLP-1") and obesity industry update.

On June 7^th, Novo Nordisk® ("Novo") announced that over three million Wegovy® pill prescriptions had been filled since its initial launch on January 5, 2026, in what they call "one of the strongest US pharmaceutical launches by volume on record". They also offered the information that 82% of those prescriptions went to people previously untreated with GLP-1 medications, supporting Lexaria's long-held thesis that orally-delivered GLP-1 would greatly expand the marketplace in comparison to injectable delivery.

Just four days earlier, on June 3^rd, Novo announced that Wegovy® pills were being launched in the United Arab Emirates for purposes of weight-loss. Novo further announced, on June 11^th, that Wegovy® had been approved in the United Kingdom as the first daily GLP-1 weight-loss pill in that country, demonstrating the continued expansion around the world of orally-delivered GLP-1 medications specifically indicated for weight loss.

Not to be outdone, in recent weeks Eli Lilly and Company® ("Lilly") announced a series of results from its Phase 3 trials on retatrutide, an investigational drug targeting GLP-1, glucagon, and GIP ("glucose-dependent insulinotropic polypeptide") receptors. In their Phase 3 TRIUMPH-1 study of 2,339 people, retatrutide injected at 12mg once weekly resulted in an average weight loss of 28.3% over an 80-week period. This degree of weight loss was so extensive as to cause 65.3% of people to reach a BMI of under 30, meaning that they no longer met the BMI criteria for obesity.

In that same study, retatrutide reduced knee osteoarthritis pain by 73.1% and moderate-to-severe obstructive sleep apnea severity by up to 60.6% per hour. This broadening of applications of GLP-1 drugs has long been envisioned as an extremely important byproduct of effective weight loss treatments:

"Obesity drives more than 200 downstream diseases, yet we have historically treated those conditions one at a time and in silos," said Ania Jastreboff, M.D., Ph.D., Professor of Medicine & Pediatrics (Endocrinology) at the Yale School of Medicine, Director of the Yale Obesity Research Center (Y-Weight), and lead investigator. "In TRIUMPH-1 and TRANSCEND-T2D-1, treatment with retatrutide resulted in substantial weight reduction together with clinically meaningful improvements in glycemia, knee osteoarthritis pain, and obstructive sleep apnea, with many individuals reaching what are classified as healthy-range weight and normal blood sugar levels."

On June 8^th, Lilly released results from its ACHIEVE Phase 3 trials that demonstrated that their daily oral GLP-1 drug, Foundayo® (orforglipron), lowered A1C levels by 2.2% from a baseline of 8.3% to just 6.1%: a reduction of 26.5% over a period of 52 weeks. Foundayo® is being investigated as a potential treatment for all of type 2 diabetes, obstructive sleep apnea, weight management, hypertension, osteoarthritis knee pain, peripheral artery disease, and stress urinary incontinence.

A very large dataset of more than 2 million veterans revealed that GLP-1 drugs offer potentially significant benefits to neurological and behavioral health with reduced risks of addiction to substances such as alcohol, cannabis, stimulants and opioids, as well as a decreased risk of neurocognitive disorders such as Alzheimer's and dementia where they have evidenced reduced inflammation in the brain. Also confirmed in the dataset were earlier discoveries of the drug's potential to lower the risk of heart attack, stroke, high cholesterol, and other cardiovascular conditions. Other studies have pointed to benefits experienced by persons with chronic kidney disease, metabolic dysfunction-associated steatohepatitis (MASH), and arthritis.

It can no longer be a surprise that revenue forecasts for these drugs are surging, as Lexaria earlier noted: TD Cowen® raised their previous 2030 sales forecast of the overall GLP-1 sector from $101 billion to $139 billion, Roots Analysis is forecasting sales of $180 billion by 2035, while UBS Investment Bank® expects 2029 GLP-1 sales to reach $126 billion.

The obesity and diabetes markets continue to be dominated by Lilly and Novo. Naysayers expected the excitement of the popular weight loss drugs to fade but they could not have been more wrong. If anything, the scale of investigation is increasing and new drug possibilities are accelerating - not consolidating. According to IQVIA, more than 193 obesity pipeline assets are in active clinical development with 8 more novel GLP-1 drug approvals expected in the next 4 years.

Effectiveness of these drugs is no longer in question and may be reaching practical limitations when it comes to weight loss (above). The largest opportunity for product improvement is in the area of patient safety. The existing medications in the market today notoriously cause unwanted adverse events ("AEs"), more specifically gastrointestinal ("GI") AEs (nausea, vomiting, diarrhea, and constipation).

To that end, Lexaria is working to position its DehydraTECH™ (also referred to as "DHT") drug delivery technology as not only an improved drug absorption/performance enhancer, but also as a vital enabler of reducing side effects of various GLP-1 drugs. Lexaria continues to advance its DehydraTECH™ pipeline by launching two new animal studies this year on drugs never before tested for compatibility with our technology: retatrutide and amycretin. The following table summarizes the dramatic improvements in GI AEs that Lexaria has realized when testing three (semaglutide, tirzepatide, and liraglutide) of the major GLP-1 drugs on the market today with its DehydraTECH™ technology in an oral format:

* oral dosing was performed after overnight fasting in all instances, except for GLP-1-H24-2 where fed pre-dosing conditions were applied.

** partial/8-week results from 12-week study

With our extensive wholly-owned patent portfolio protecting DehydraTECH™ worldwide, Lexaria continues to take steps to unlock the value of its robust drug delivery platform and continues to discuss business development opportunities with interested commercial partners. As the diabetes control and weight-loss industries continue to focus on GLP-1 and even more advanced drug generations for these and other therapeutic indications, Lexaria remains confident that DehydraTECH™ is valid for utilization with the right commercial partner(s).

About Lexaria Bioscience Corp. & DehydraTECH™

DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH^TM has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
[email protected]
Phone: 250-765-6424, ext. 202

SOURCE: Lexaria Bioscience Corp.

Retatrutide and amycretin are being investigated for compatibility with Lexaria's proprietary DehydraTECH^™

KELOWNA, BC / ACCESS Newswire / June 9, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that dosing has been completed in its 2026 Animal Study #2 (GLP-1-A26-2) evaluating a number of formulation enhancements with 2 next-generation glucagon-like peptide-1 ("GLP-1") drugs (the "Study") to explore the potential for improved DehydraTECH^TM performance as well as potentially stake new intellectual property claims.

Retatrutide is one of Eli Lilly and Company's^® leading next-generation GLP-1 drugs undergoing extensive trials in the weight loss space, where two current Phase 3 studies were recently reported to deliver average weight loss of 28.3% - or 70 pounds - when evaluating patients who stayed on the drug. Unlike the GLP-1 drugs currently on the market, retatrutide is a triple hormone receptor agonist, targeting each of GLP-1, glucagon, and GIP ("glucose-dependent insulinotropic polypeptide"). Retatrutide is currently administered only via weekly injections, whereas Lexaria's Study will examine oral dosing formulated via tablets and capsules.

Weight loss with retatrutide - which has not yet been approved by the FDA - seems to be higher than with any other GLP-1 drug on the market today, with an astonishing 65.3% of participants taking the 12mg dose of retatrutide achieving a BMI ("body mass index") of less than 30, meaning they no longer met the minimum BMI criteria for obesity.

Lexaria's investigation into retatrutide, if successful, would expand DehydraTECH's applicability to prospective triple-agonist weight-loss peptide drugs in late stages of development, that could potentially dominate the future market.

"This is a watershed moment for Lexaria's investigations into GLP-1 drugs," said Richard Christopher, CEO of Lexaria Bioscience. "We have already established the compatibility of our technology with today's leading GLP-1 drugs, but if we are likewise able to demonstrate benefits with the drugs of tomorrow like retatrutide, amycretin and others, then we will begin to show relevance to those drugs that will likely be on the market for the next 10 years or more."

Lexaria's large Study is investigating 18 different study arms to evaluate new and novel DehydraTECH^TM compositions that may be of interest to industry. Blood samples are being taken at multiple timepoints through a 24-hour post-dosing period to quantify the pharmacokinetic ("PK") performance of each composition. The primary goals of this Study are to investigate compatibility of retatrutide and amycretin with Lexaria's DehydraTECH^TM formulation and processing technology, centered around PK performance and tolerability. Retatrutide is owned by Eli Lilly and Company^®, whereas amycretin is owned by Novo Nordisk^®.

As is the case with all GLP-1 drugs on the market today, common side effects of next-generation retatrutide and amycretin GLP-1 drugs include nausea and gastrointestinal issues such as diarrhea and vomiting. With this Study and others planned, Lexaria is attempting to establish that DehydraTECH^TM processing of these drugs may lower the severity and instances of side effects while maintaining or improving efficacy.

This Study will also directly compare pill (tablet) formulations to capsules, to better understand the differences between absorption of the active drugs primarily through either the stomach (pills) or the intestine (capsules). Most oral GLP-1 peptide drugs on the market today rely on pill formulations that are primarily absorbed through the stomach.

As in Animal Study #1 announced on April 15th, this new Study will evaluate alternative formulations to the salcaprozate sodium (SNAC) technology currently incorporated in Novo Nordisk's^® oral Rybelsus^® and Wegovy^® tablet products. The present Study will include but not be limited to compositions using a different delivery enabling compound, sodium caprate, which has itself been shown to influence gastrointestinal absorption.

This is a self-sponsored Lexaria Study that is fully funded from existing corporate resources.

About Lexaria Bioscience Corp. & DehydraTECH^TM

DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH^TM has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH^TM technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

INVESTOR CONTACT:

George Jurcic - Head of Investor Relations
[email protected]
Phone: 250-765-6424, ext 202

SOURCE: Lexaria Bioscience Corp.

KELOWNA, BC / ACCESS Newswire / June 3, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that it is attending the BIO International Convention ("BIO") from June 22-25 in San Diego, CA. Lexaria's attendance at last year's 2025 BIO convention served as a catalyst for its greatly expanded business development ("BD") program that is now starting to deliver positive results and which Lexaria intends to build upon at this year's BIO conference.

"We are experiencing record-high levels of business development and collaboration interest in our DehydraTECH platform, even before the upcoming BIO conference," said Richard Christopher, CEO of Lexaria Bioscience. "New business relationships require intense energy and scientific evaluation from both prospective partners to discover the best fit possible. We are working tirelessly in this regard with the intent of generating positive developments that we can publicly discuss."

BIO is the largest convention of its kind, with over 20,000 attendees expected from all corners of the global pharmaceutical and biotechnology industries, as well as their supporting sectors such as investors and finance professionals, and more. BIO is focused on intra-industry collaborations and meetings, with over 66,000 partnering meetings having taken place at the 2025 conference. Lexaria has already begun reserving meetings and will be fully booked for the event given the strong industry interest in its proprietary DehydraTECH^™ drug delivery platform.

BIO is only the latest example of a multi-faceted BD program that Lexaria quietly launched in order to inform prospective business partners of the benefits available through DehydraTECH^™. Although confidential information, by its nature, cannot be publicly disclosed, Lexaria's BD program has already generated a number of collaborative and potential business partnering discussions with a wide range of companies from innovative smaller biotech developers to well-known global pharmaceutical giants.

While Lexaria's BD program has already developed a number of ongoing discussions, it continues to develop additional early-stage leads, and the Company intends to thoroughly evaluate each potential relationship, large and small, and ultimately only pursue those that are in the best interests of its shareholders. Additional information will be made available when appropriate.

About Lexaria Bioscience Corp. & DehydraTECH

DehydraTECH^™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
[email protected]
Phone: 250-765-6424, ext. 202

SOURCE: Lexaria Bioscience Corp.